Primary Hyperaldosteronism (B)
This patient most likely has primary hyperaldosteronism (PA) as the cause of her secondary hypertension, evidenced by resistant hypertension requiring multiple agents, borderline hypokalemia (K 3.5), and clinical improvement with spironolactone—a mineralocorticoid receptor antagonist that specifically targets the pathophysiology of PA 1, 2.
Clinical Reasoning Algorithm
Why Primary Hyperaldosteronism is Most Likely:
Resistant hypertension profile: She requires 5 antihypertensive medications (ACEI, BB, CCB, hydrochlorothiazide, spironolactone) and still has suboptimal control (BP 145 systolic). PA is the most common cause of secondary hypertension and is strongly associated with treatment resistance 2.
Response to spironolactone: The fact that her BP improved after adding spironolactone is highly suggestive. Spironolactone is the first-line medical treatment for PA and works by blocking the mineralocorticoid receptor, directly addressing aldosterone excess 1.
Borderline hypokalemia: While classic teaching emphasizes spontaneous hypokalemia in PA, many patients present with normal-low potassium (3.5 mmol/L in this case). Modern guidelines recognize that hypokalemia is NOT required for PA diagnosis—normokalemic PA is actually more common 2.
Left ventricular hypertrophy: PA patients have significantly increased risk of LVH compared to essential hypertension patients with similar BP levels (OR 2.29), reflecting the direct cardiac effects of aldosterone excess beyond BP elevation 1.
Elevated creatinine: The creatinine of 162 μmol/L (approximately 1.8 mg/dL) likely represents hypertensive nephropathy from longstanding uncontrolled hypertension rather than primary renal disease causing the hypertension.
Why NOT the Other Options:
Chronic renal failure (A): While the creatinine is elevated, this is more likely a consequence of longstanding severe hypertension rather than the cause. True renal parenchymal disease causing secondary hypertension typically presents with more advanced renal dysfunction, proteinuria, and abnormal urinalysis. The improvement with spironolactone points away from primary renal disease.
Renal artery stenosis (D): The absence of an abdominal bruit makes this less likely, though bruits are neither sensitive nor specific. More importantly, she's already on an ACEI—if she had significant bilateral RAS or stenosis in a solitary kidney, the ACEI would likely have caused acute kidney injury or worsening renal function. The clinical response to spironolactone rather than optimization of RAS blockade argues against this diagnosis 3.
Pheochromocytoma (C): This typically presents with paroxysmal symptoms (episodic headaches, palpitations, sweating), labile rather than sustained hypertension, and would not show preferential response to spironolactone. The physical exam is described as unremarkable without mention of these classic features.
Diagnostic Confirmation Needed
To definitively confirm PA, she requires:
- Aldosterone-to-renin ratio (ARR) as screening test: PAC > 20 ng/dL with suppressed renin is highly suggestive 2
- Confirmatory testing: Saline infusion test, oral salt loading, or captopril challenge test (after correcting any residual hypokalemia) 2
- Subtype differentiation: CT adrenal imaging followed by adrenal venous sampling to determine if unilateral (potentially curable with adrenalectomy) versus bilateral disease (requiring continued medical therapy) 1
Critical Clinical Pitfall
Common mistake: Assuming normal potassium excludes PA. The majority of PA patients are normokalemic, and waiting for spontaneous hypokalemia to screen for PA results in significant underdiagnosis 2. Any patient with resistant hypertension should be screened for PA regardless of potassium level.
The therapeutic response to spironolactone in this case is both diagnostic and therapeutic, strongly supporting PA as the underlying etiology 1.